Targeting ALK - Discovery to Frontline Treatment

A 'keynote' on the discovery of ALK aberrations in neuroblastoma, their significance at diagnosis and at relapse, drug development strategies and plans to incorporate ALK inhibitors into frontline therapy with potential joint COG and SIOPEN studies. Also including germline ALK mutation.

Moderated by Gavin Lindberg, Co-Founder & President, The EVAN Foundation